Table 2 Clinical Characteristics of Cohort 2
From: Effects of body mass index on the immune response within the first days after major stroke in humans
Variable | Patient Group (N = 17) | Control Group (N = 17) |
|---|---|---|
Age (Years; Mean ± SD) | 70 (± 12.1) | 70 (± 7.2) |
Sex [as % female] | 6 (35.3%) | 9 (52.9%) |
BMI [Mean ± SD] | 28.4 (± 4.1) | 28.9 (5.5%) |
Weight Categories | ||
Obese [n (%)] | 6 (35.3%) | 5 (29.4%) |
Overweight [n (%)] | 7 (41.2%) | 8 (47.1%) |
Normal [n (%)] | 4 (23.5%) | 4 (23.5%) |
Comorbidities | ||
Hypertonia (n (%)) | 16 (94.1%) | 12 (70.6%) |
Dyslipidemia (n (%)) | 9 (52.9%) | 9 (52.9%) |
Diabetes mellitus (n (%)) | 3 (17.6%) | 6 (35.3%) |
Stroke Characteristics | ||
Etiology | ||
Large-artery atherosclerosis | 3 (17.6) | NA$ |
Cardioembolism [n (%)] | 9 (53.0) | NA$ |
Stroke of other determined etiology [n (%)] | 2 (11.8) | NA$ |
Stroke of undetermined etiology [n (%)] | 3 (52.9) | NA$ |
NIHSS score (Median (IQR)) | 12 (6) | NA$ |
Treatment ((n (%))& | 15 (88.2% | NA$ |
Systemic thrombolysis (n (%))& | 13 (76.5%) | NA$ |
Mechanical thrombolysis (n (%))& | 7 (41.2%) | NA$ |
Combined treatment (n (%))& | 5 (29.4%) | NA$ |
Stroke size, cm3 (Mean ± Std)* | 83.3 (± 59.3) | NA$ |